Table 3 Outcomes of patients receiving intravenous PMB
Outcomes | n (%) |
|---|---|
Bacteria eradication rate, n (%) | 66 (77.65) |
Treatment duration, median (IQR) | 11 (9, 13) |
Adverse events, n (%) | 16 (16) |
 Nephrotoxicity | 7 (7) |
 Neurotoxicity | 6 (6) |
 Skin hyperpigmentation | 3 (3) |
 Eosinophil increase | 7 (7) |
ICU mortality, n (%) | 12 (12) |
Hospital mortality, n (%) | 15 (15) |
28-day mortality, n (%) | 40 (40) |